Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Health Canada & HTA Body CADTH To Offer Parallel Scientific Advice

Executive Summary

Canada has launched a new initiative under which drug sponsors will be able to request parallel scientific advice for regulatory and health technology assessment purposes.

You may also be interested in...



England And Canada Collaborate On Parallel Scientific Advice For HTA

Health technology appraisal institutes in England and Canada are joining forces to offer parallel scientific advice and both agencies say they are open to more international collaborations.

International HTA Agencies Collaborate On How To Determine Value-Based Prices

Health technology assessment agencies in the US, the UK and Canada are working together to develop new ways of determining value-based prices for potentially curative treatments like gene therapies.

Canada To Speed Market Access With Aligned HTA And Marketing Authorization Reviews

Drug sponsors can opt into the newly launched Canadian parallel review scheme at any stage of the marketing authorization review process, but the earlier they do so the better.

Topics

UsernamePublicRestriction

Register

PS124883

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel